Search results
Results from the WOW.Com Content Network
BOSTON (Reuters) -The U.S. Justice Department on Wednesday accused Regeneron Pharmaceuticals of manipulating Medicare's drug-pricing process by inflating the average sales price for its expensive ...
Regeneron's shares fell marginally to $961.78 in early trading. The company was looking to expand its oncology portfolio with odronextamab, beyond its lone approved skin cancer drug, Libtayo
On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69. The company reported sales of $3.72 ...
Regeneron has a robust business that has allowed it to get to the position where it is today, where a stock split could be a justifiable move. But ultimately, it depends on management and whether ...
Regeneron's shares closed down 8.6% at $715.9. The U.S. Food and Drug Administration issued a complete response letter, indicating the agency has review US FDA declines to approve Regeneron's ...
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Regeneron was seeking regulatory approval of its therapy, linvoseltamab, in patients with multiple myeloma whose cancer has returned or worsened after at least three prior lines of treatment. The ...